41 – 60 of 2172
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old with Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial
(
- Contribution to journal › Letter
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
Clinical Implications of Discrepancy between One-stage Clotting and Chromogenic Factor IX Activity in Haemophilia B
2023) In Thrombosis and Haemostasis(
- Contribution to journal › Article
-
Mark
IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate
ETV6::RUNX1-positive leukemia cells in preclinical models.
(
- Contribution to journal › Article
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group
(
- Contribution to journal › Article
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A : The LEOPOLD Kids Trial
(
- Contribution to journal › Article
-
Mark
The International Consensus Classification of acute myeloid leukemia
(
- Contribution to journal › Scientific review
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
-
Mark
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID-19 susceptibility, severity, and long COVID-19
(
- Contribution to journal › Article
-
Mark
Intracranial Hemorrhages in Neonates : Incidence, Risk Factors and Treatment
(
- Contribution to journal › Article
-
Mark
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
(
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Contribution of rare and common coding variants to haematological malignancies in the UK biobank
(
- Contribution to journal › Letter
-
Mark
F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project.
(
- Contribution to journal › Article